Out Come Study To Define Laboratory Parameters That Are Best Suited to Diagnose Functional Iron Deficiency (SFIDS)

Swiss Functional Iron Deficiency Study

The purpose of the study is to define laboratory parameters which are best suited to diagnose functional iron deficiency. Functional iron deficiency is a condition where - due to the lack of iron bioavailability - the patient suffers from symptoms such as fatigue and weakness, or his/her capacity to produce red blood cells is reduced.

Study Overview

• Status: Completed
• Conditions: Functional Iron Deficiency
• Intervention / Treatment: Procedure: %-hypo (laboratory parameter, functional iron deficiency); Procedure: CHr (laboratory parameter, functional iron deficiency); Procedure: RET-HE (laboratory parameter, functional iron deficiency)

Detailed Description

In dialysis patients the degree of anemia is highly correlated to both morbidity and mortality. A drop in Hb by 10 g/L translates into an increase in the rate of hospitalizations of 5 to 6 % and a rise in mortality by 4 to 5 %. The past two decades have seen great progress in the treatment of renal anemia with the advent of erythropoietin, and, more recently, darbepoetin. Quite soon, however, it became clear, that anemia in patients with chronic renal failure is complicated by a lack of bioavailable iron, which confers these patients partly resistant to treatment with erythropoietin/darbepoetin.

There are several parameters in use to estimate total body iron stores in the diagnosis of iron deficiency and iron deficiency anemia. Serum iron represents only a minor fraction of total body iron and is subject to major fluctuations due to influx or efflux from tissue iron stores. In addition, it shows a great diurnal variability, and is therefore a very poor parameter of iron deficiency. Iron saturation of its transporter protein in blood, transferrin, is similarly difficult to interpret, as it depends also in part on the determination of serum iron levels. Ferritin, the tissue iron storage protein, is released into the circulation during active liver cell damage, and, quite unlike serum transferrin levels, ferritin levels rise during the acute phase response of the inflammatory reaction. In most cases, however, the serum ferritin level, if substantiated by the concurrent determination of the C-reactive protein and the alanine-leucine-aminotransferase (ALT) to exclude both, occult liver cell damage and inflammation, correlates well with total body iron stores and total body iron deficiency, respectively.

The serum ferritin level, however, is a poor marker of functional iron deficiency when erythropoiesis is inhibited by the relative lack bioavailable iron in high turnover states of the bone marrow such as in hemolysis and in the thalassemias. Correspondingly, in patients with hemochromatosis and an increased functional iron availability, erythropoiesis will be augmented following acute blood losses.

To date no golden standard exists to measure functional iron deficiency in a routine clinical setting. As a matter of fact, in some clinical studies functional iron deficiency is still diagnosed indirectly and retrospectively by the effect of an iron substitution therapy (increase in Hb by 10 g/L following 4 weeks of iron supplementation)

The percentage of hemoglobin-deficient, hypochromic erythrocytes, as measured by some hemocytometers, reflects the availability of iron for erythropoiesis and has become a surrogate marker of functional iron deficiency. As the lifespan of erythrocytes varies according to the degree of the patient's uremia between approximately 60 and 120 days, hypochromic erythrocytes, measured as a percentage of total erythrocytes (%-Hypo), become detectable only late in the course of erythropoietin therapy, and are therefore thought by some to be of only limited sensitivity in the diagnosis of functional iron deficiency.

With the automated measurement of reticulocytes, it has become now possible on some hemocytometers, such as the Advia 120, to also determine the hemoglobin content in newly formed reticulocytes (CHr). The hemoglobin content of reticulocytes mirrors more closely the current availability of iron for erythropoiesis. What would make CHr so attractive for clinicians and the clinical laboratory, is not only its acclaimed sensitivity to detect functional iron deficiency, but, even more so, its easy availability, as it forms part of a simple reticulocyte count on a normal hemocytometer.

In other hemocytometric systems laser light scatter patterns have been utilized to characterize the hemoglobin content in reticulocytes (RET-HE). This new parameter, RET-HE, has been shown to be of a similar sensitivity and specificity as CHr and to give comparable results in clinical samples (CHr, r = 0.94).

The present study is meant to define the laboratory parameter (%-Hypo/CHr or RET-He) which is suited best to diagnose functional iron deficiency. The study design asks for the parameter with which physicians will be able to diagnose their patients so to improve the management of their anemia. A diagnostic parameter is searched for which improves the patients' treatment the most, as measured by blood hemoglobin levels (primary end point 1), at the lowest possible costs (primary end point 2).

• Study Type: Interventional
• Enrollment (Actual): 77
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Switzerland
  • Zürich
    • Zollikerberg, Zürich, Switzerland, 8125
      • Spital Zollikerberg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• renal anemia, glomerular filtration rate < 10 ml/min
• therapy with either erythropoietin or darbepoetin
• dialysis patients
• therapy with iron

Exclusion Criteria:

• cancer
• autoimmune diseases
• chronic inflammation
• liver disease
• thalassemia, and other causes of anemia (except for renal anemia and iron deficiency anemia)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change in Hemoglobin	12 months
Costs = erythropoietin/darbepoetin prescribed	12 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Changes in soluble transferrin receptor	12 months
Changes in transferrin saturation	12 months
changes in ferritin	12 months

Collaborators and Investigators

• Sponsor: Spital Zollikerberg
• Collaborators: Viollier Inc.
• Investigators: Principal Investigator: Boris E Schleifenbaum, MD, Viollier Inc.

Study record dates

Study Major Dates

• Study Start: October 1, 2004
• Study Completion (Actual): May 1, 2006

Study Registration Dates

• First Submitted: July 2, 2007
• First Submitted That Met QC Criteria: July 2, 2007
• First Posted (Estimate): July 3, 2007

Study Record Updates

• Last Update Posted (Estimate): July 3, 2007
• Last Update Submitted That Met QC Criteria: July 2, 2007
• Last Verified: July 1, 2007

More Information

Terms related to this study

• Keywords: dialysis; erythropoietin; renal anemia; darbepoetin; functional iron deficiency
• Additional Relevant MeSH Terms: Metabolic Diseases; Hematologic Diseases; Anemia, Hypochromic; Anemia; Iron Metabolism Disorders; Anemia, Iron-Deficiency; Physiological Effects of Drugs; Trace Elements; Micronutrients; Iron
• Other Study ID Numbers: SFIDS-2004